Alzheimer's Disease Pathogenesis

Abstract:  Alzheimer's disease (AD) is the chief cause of dementia, and age is its major risk factor. The majority of cases (90–95%) are sporadic (SAD), and the remainder are familial (FAD). AD is characterized by two brain lesions, intraneuronal fibrillary tangles and extracellular plaques. The lesions are identical in SAD and FAD as well as to those in persons with Down's syndrome (DS). The same lesions are also observed frequently in elderly non‐demented individuals (E‐ND). Both AD lesions may stem from the normal progressive increases in oxidative stress (OxS) throughout the body with age. Onset of dementia due to the accumulating lesions is around 40 years for DS, 40–60 years for FAD, over about 65 years for SAD, while that for E‐ND is unknown. The lesions are made clinically manifest with time by the normal increase with age of OxS, “the dementia of old age,” or by a process specific for each AD category, which enhances the normal OxS so as to lower the unknown onset age of dementia for E‐ND individuals to that associated with the AD category. A plausible process can be advanced for each AD category. The hypothesis suggests convenient, effective measures to prevent and treat, for example, by decreasing brain OxS levels with oral antioxidants such as lipoic or dehydroascorbic acids that are capable of passing the blood–brain barrier.

[1]  B. Yankner Mechanisms of Neuronal Degeneration in Alzheimer's Disease , 1996, Neuron.

[2]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[3]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[4]  H. Loetscher,et al.  The Influence of Endoproteolytic Processing of Familial Alzheimer's Disease Presenilin 2 on Aβ42 Amyloid Peptide Formation* , 1999, The Journal of Biological Chemistry.

[5]  D. Allsop,et al.  The occult aftermath of boxing. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[6]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[7]  R. Katzman.,et al.  Alzheimer Disease: Basic and Clinical Advances , 1991, Journal of the American Geriatrics Society.

[8]  A. Guterman,et al.  Neurological Sequelae of Boxing , 1987, Sports medicine.

[9]  Y. Tu,et al.  Effect of ganglioside GM3 on the activity and conformation of reconstituted Ca2+‐ATPase , 1996, FEBS letters.

[10]  M. Mattson,et al.  Presenilin-1 Mutation Increases Neuronal Vulnerability to Focal Ischemia In Vivo and to Hypoxia and Glucose Deprivation in Cell Culture: Involvement of Perturbed Calcium Homeostasis , 2000, The Journal of Neuroscience.

[11]  R. Katzman.,et al.  Advances in Alzheimer's disease , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  L. Lue,et al.  Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.

[13]  D. Harman,et al.  Free radical theory of aging: Alzheimer’s disease pathogenesis , 1995, AGE.

[14]  S. Orrenius,et al.  Role of calcium in toxic and programmed cell death. , 1991, Advances in experimental medicine and biology.

[15]  S. Sorbi,et al.  Alteration of acylphosphatase levels in familial Alzheimer's disease fibroblasts with presenilin gene mutations , 1996, Neuroscience Letters.

[16]  M. Mattson,et al.  Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. , 2008, Journal of neurochemistry.

[17]  C. W. Adams,et al.  The cerebral vasculature in dementia pugilistica. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[18]  K. Beyreuther,et al.  Prospects for pharmacological intervention in Alzheimer disease. , 2000, Archives of neurology.

[19]  J. Stamler,et al.  Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. , 1998, Science.

[20]  S. Perry,et al.  Sites on the cytoplasmic region of phospholamban involved in interaction with the calcium-activated ATPase of the sarcoplasmic reticulum. , 1999, European journal of biochemistry.

[21]  R. Martins,et al.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. , 1989, The New England journal of medicine.

[22]  S. Schuchmann,et al.  Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down's syndrome. , 2000, Free radical biology & medicine.

[23]  N. Larsson,et al.  Revolution in mitochondrial medicine , 1999, FEBS letters.

[24]  M. Goedert,et al.  Risky apolipoprotein in brain , 1994, Nature.

[25]  Michael J. Berridge,et al.  Inositol phosphates and cell signalling , 1989, Nature.

[26]  B. Yankner New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. , 1996, Nature medicine.

[27]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Richard J. Miller The control of neuronal Ca2+ homeostasis , 1991, Progress in Neurobiology.

[29]  D. Harman Alzheimer's Disease: Role of Aging in Pathogenesis , 2002, Annals of the New York Academy of Sciences.

[30]  N Howell,et al.  Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Selkoe,et al.  The Transmembrane Aspartates in Presenilin 1 and 2 Are Obligatory for γ-Secretase Activity and Amyloid β-Protein Generation* , 2000, The Journal of Biological Chemistry.

[32]  D. Mann,et al.  The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome , 1989, Journal of the Neurological Sciences.

[33]  D. Harman Alzheimer’s disease: A hypothesis on pathogenesis , 2000, Journal of the American Aging Association.

[34]  J. East,et al.  An investigation of the mechanism of inhibition of the Ca(2+)-ATPase by phospholamban. , 1996, The Biochemical journal.

[35]  A. Roses,et al.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. , 1994, The Journal of clinical investigation.

[36]  D. Wallace,et al.  Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. , 1996, American journal of medical genetics.

[37]  E. Storey,et al.  The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not actively motile portions of neurites , 1996, Brain Research.

[38]  D. Alkon,et al.  Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  D. Harman Aging: Prospects for further increases in the functional life span , 1994, AGE.

[40]  L. Wolfson,et al.  Clinico‐pathologic studies in dementia , 1988, Neurology.

[41]  D. Graham,et al.  βA4 amyloid protein deposition in brain after head trauma , 1991, The Lancet.

[42]  T. Ozawa Mitochondrial DNA Mutations and Age , 1998, Annals of the New York Academy of Sciences.

[43]  J. Mocco,et al.  Dehydroascorbic acid, a blood–brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Goldman,et al.  Oxidative stress up‐regulates IL‐8 and TNF‐α synthesis by human dendritic cells , 1998, European journal of immunology.

[45]  J. Blass,et al.  Systemic manifestations of Alzheimer’s disease , 1988, AGE.

[46]  C Oliver,et al.  Down's Syndrome and Alzheimer's disease: a review , 1986, Psychological Medicine.

[47]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[48]  D. Maclennan,et al.  Phospholamban Regulates the Ca2+-ATPase through Intramembrane Interactions* , 1996, The Journal of Biological Chemistry.

[49]  D. Harman Aging: Phenomena and Theories , 1998, Annals of the New York Academy of Sciences.

[50]  D. Blacker,et al.  The genetics of Alzheimer disease: current status and future prospects. , 1998, Archives of neurology.

[51]  K. Beyreuther,et al.  Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. , 1992, The Journal of biological chemistry.

[52]  R. Schlapbach,et al.  Oxidants in mitochondria: from physiology to diseases. , 1995, Biochimica et biophysica acta.

[53]  P. Fraser,et al.  The Presenilin 1 Protein Is a Component of a High Molecular Weight Intracellular Complex That Contains β-Catenin* , 1998, The Journal of Biological Chemistry.

[54]  David L. Stokes,et al.  Structure of the calcium pump from sarcoplasmic reticulum at 8-Å resolution , 1998, Nature.

[55]  T D Koepsell,et al.  The association between head trauma and Alzheimer's disease. , 1990, American journal of epidemiology.

[56]  D. Harman Free Radical Theory of Aging: Increasing the Average Life Expectancy at Birth and the Maximum Life Span , 1999 .

[57]  Bing-sheng Li,et al.  α-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway , 2001, Neuroscience Letters.

[58]  C. Behl,et al.  Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.

[59]  A. Zahradníková,et al.  Inhibition of the skeletal muscle ryanodine receptor calcium release channel by nitric oxide , 1996, FEBS letters.

[60]  J. Weber,et al.  Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. , 1992, Science.

[61]  R. S. Sohal,et al.  Hydrogen peroxide release by mitochondria increases during aging , 1991, Mechanisms of Ageing and Development.

[62]  M. Mattson,et al.  Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Kühlbrandt,et al.  Three-dimensional map of the plasma membrane H+-ATPase in the open conformation , 1998, Nature.

[64]  E M Wijsman,et al.  A familial Alzheimer's disease locus on chromosome 1 , 1995, Science.

[65]  K. Kosik,et al.  Neuritic pathology and dementia in alzheimer's disease , 1991, Annals of neurology.

[66]  D. Dickson,et al.  The Pathogenesis of Senile Plaques , 1997, Journal of neuropathology and experimental neurology.

[67]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[68]  D. Selkoe Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.

[69]  E. Masliah,et al.  Structural basis of the cognitive alterations in Alzheimer disease. , 1994 .

[70]  S. Orrenius,et al.  Cytoskeletal alterations in human platelets exposed to oxidative stress are mediated by oxidative and Ca2+-dependent mechanisms. , 1989, Archives of biochemistry and biophysics.

[71]  D. Harman Aging: a theory based on free radical and radiation chemistry. , 1956, Journal of gerontology.

[72]  D. Harman Free radical theory of aging: history. , 1992, EXS.

[73]  G. Barja Mitochondrial Oxygen Radical Generation and Leak: Sites of Production in States 4 and 3, Organ Specificity, and Relation to Aging and Longevity , 1999, Journal of bioenergetics and biomembranes.

[74]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[75]  N. Green,et al.  The Mechanism of Ca 2 1 Transport by Sarco ( Endo ) plasmic Reticulum Ca 2 1-ATPases * , 1997 .

[76]  S. Dimauro,et al.  Mitochondrial involvement in Alzheimer's disease. , 1999, Biochimica et biophysica acta.

[77]  Y. Wang,et al.  Antagonistic effect of ganglioside GM1 and GM3 on the activity and conformation of sarcoplasmic reticulum Ca2+‐ATPase , 1999, FEBS letters.

[78]  N. Green,et al.  The Mechanism of Ca2+ Transport by Sarco(Endo)plasmic Reticulum Ca2+-ATPases* , 1997, The Journal of Biological Chemistry.

[79]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[80]  B. Yankner,et al.  Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro , 1995, Nature.